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Abstract 
Distributional cost-effectiveness analysis (DCEA) is a framework for incorporating health inequality concerns into the economic evaluation of health sector interventions.  In this tutorial we describe the technical details of how to conduct DCEA, using an illustrative example comparing alternative ways of implementing the NHS Bowel Cancer Screening Programme (BCSP).  The two key stages in DCEA are (A) modelling social distributions of health associated with different interventions and (B) evaluating social distributions of health with respect to the dual objectives of improving total population health and reducing unfair health inequality.  As well as describing the technical methods used, we also identify the data requirements and the social value judgements that have to be made.  Finally, we demonstrate the use of sensitivity analyses to explore the impacts of alternative modelling assumptions and social value judgements.
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1.	INTRODUCTION
When designing and prioritising interventions, health care decision makers often have concerns about reducing unfair health inequality as well as improving total population health.  However, the economic evaluation of such interventions is typically conducted using methods of cost-effectiveness analysis (CEA) which focus exclusively on maximising total population health.  These standard methods of CEA do not provide decision makers with information about the health inequality impacts of the interventions evaluated, or the nature and size of any trade-offs between improving total population health and reducing unfair health inequality.
To address these shortcomings we have developed a framework for incorporating health inequality impacts into CEA, which we call “distributional cost-effectiveness analysis” (DCEA) (1).  DCEA is suitable for health sector decisions concerning the design and prioritisation of any type of health care intervention with an explicit health inequality reduction objective – potentially including treatments as well as preventive health care such as programmes of health promotion, screening, vaccination, case finding, primary and secondary prevention of chronic disease, and so on.  However, like standard CEA, it focuses exclusively on health benefits and opportunity costs falling on the health sector budget.  DCEA therefore does not provide a fully general framework of distributional economic evaluation for evaluating the health and income inequality impacts of cross-government public health programmes with important non-health benefits and opportunity costs falling outside the health sector budget.
The DCEA framework has two main stages: (A) modelling social distributions of health associated with each intervention, and (B) evaluating social distributions of health.  The main steps in the modelling stage are:
A1.	estimating the baseline health distribution; 
A2. 	modelling changes to this baseline distribution due to the health interventions being compared, allowing for the distribution of opportunity costs from additional resource use;
A3.	adjusting the resulting modelled health distributions for alternative social value judgements about fair and unfair sources of health variation; 
And the main steps in the evaluation stage are:
B1.  	using the estimated distributions to quantify the change in total population health and 
unfair health inequality due to each intervention;
B2.	ranking the interventions based on dominance criteria; and finally
B3.	analysing any trade-offs between improving population health and reducing unfair health inequality, allowing for alternative specifications of the underlying social welfare function.
We have previously applied  the DCEA framework to analyse four possible options for promoting increased uptake of the NHS Bowel Cancer Screening Programme (BCSP) in England (2).  In this tutorial we work through this applied example to describe the key steps in conducting a DCEA. 
The BCSP is a biennial self-test based screening programme targeted at 60-74 year olds that aims to detect and treat colorectal cancer (CRC) early, and has been shown to reduce CRC related mortality risk by a substantial proportion.  Individuals in the relevant age range are sent a guaiac faecal occult blood test (gFOBT) kit in the mail and are expected to complete the test by collecting 3 stool samples over a period of a few days and post them back for laboratory analysis.  Those individuals testing positive are invited for further diagnostic testing (follow up colonoscopy) and, where appropriate, treatment.  
Analysis of the BCSP pilots and early data from the roll out of the BCSP have indicated large variations in uptake of the screening programme patterned by the social variables of area deprivation, sex and ethnicity.  This variation in uptake can be modelled through to estimate its impact on mortality and morbidity for the different socio-economic subgroups in the population, and hence to describe the impact of the screening programme on both the average level of health and on the social distribution of health in the population.
2.	METHODS
2.1 Stage A: Modelling Social Distributions of Health 
2.1.1 Estimating the baseline health distribution
The first step in DCEA is to describe the baseline distribution of health, taking into account variation in both length and health related quality of life.  This baseline distribution will need to include the full general population, and not just the population of recipients of the intervention.  This is for two reasons.  First, the full general population is typically the relevant population for characterising policy concern with health inequality.  Second, within the context of a national, budget constrained system such as the NHS, additional resources used by recipients of an intervention will displace activities that could have been provided to anyone within the full general population. 
This baseline distribution of health should be able to describe variation in health among multiple different subgroups in the population as defined by relevant population characteristics, allowing for the correlation structure between these various characteristics.  The relevant population characteristics include not only dimensions of direct equity concern (e.g. income, ethnicity) but also characteristics necessary to estimate expected costs and effects and which may or may not generate further equity concern (e.g. sex).  The latter of these is standard for any CEA, while the former we discuss further throughout this tutorial.  The health metric we use in this context is quality adjusted life expectancy (QALE) at birth, though other suitable health metrics could also be used – such as disability adjusted life expectancy at birth or age-specific QALE – so long as they are measured on an interpersonally comparable ratio scale suitable for use within CEA.
The population characteristics of interest in this case study – those by which a substantial variation in uptake of the BCSP was observed – are sex, area level deprivation and area level ethnic diversity.  The first step in estimating our population QALE distribution is to estimate life expectancy (LE) according to each of these characteristics.  Area level deprivation in the BCSP evaluation studies was measured based on index of multiple deprivation (IMD 2004) quintile groups, and area level ethnic diversity was based on the percentage of people in the area originating from the Indian Subcontinent, again split into quintile groups (3). National statistics data are available by sex and deprivation level/social class but are not available by our particular measure of ethnic diversity.  We therefore did not include correlations with ethnic diversity in our estimation of the baseline health distribution and instead, for the purposes of the analysis, assumed its distribution is independent of deprivation and sex.
A full description of how the baseline health distribution was calculated can be found in the appendix. A summary of this QALE distribution by health quintile is shown in Figure 1.  This forms the baseline health distribution that we will use in our analysis. 
FIGURE 1 approximately here
2.1.2 Estimating the distribution of health changes due to the interventions
In order to evaluate changes in the baseline health distribution that could be attributed to the use of alternative interventions, it is necessary to know how the costs and effects of the intervention differ between the relevant subgroups, and how the opportunity costs of any change in resource use differ by those same subgroups.
Having estimated a baseline health distribution we next turn to modelling how this health distribution is impacted by the BCSP and alternative ways of promoting increased uptake of the BCSP.  We do this using an existing cost-effectiveness model of the BCSP that simulates the natural history of CRC and the impact of screening and treatment on this natural history (4)(5).  We adapt the model to look at the distributional health impacts of four different screening strategies:
I.	“No Screening”: the baseline social distribution of health
II.	“Standard Screening” as implemented in the BCSP
III.	“Targeted reminder”: Screening plus a targeted enhanced reminder letter (personal GP signed letter and tailored information package) sent only to those living in the most income deprived small areas (IMD4 and IMD5) as well as to those living in areas with the highest proportion of inhabitants from the Indian Subcontinent (IS5). 
IV.	“Universal reminder”: Screening plus a universal basic reminder letter (sending a GP endorsed reminder letter to all eligible patients). 
Impacts are first estimated by subgroup and then combined to evaluate the impact of the screening strategies on the overall social distribution of health.  
There are a number of parameters in the model that can vary by subgroup, including:
1.	Disease prevalence, severity, mortality rate and natural history - we assume in our case study that bowel cancer specific parameters are constant across our population subgroups.  The evidence available (6) broadly supports this assumption, though more detailed data at the subgroup level would be required to validate this assumption.
2.	Uptake of the intervention – the impact of gFOBT uptake by subgroup is the key difference between the various implementations of the screening programme. We discuss in detail below how this parameter is estimated for each subgroup. We also estimate the uptake of follow up colonoscopy by subgroup for those people that are invited back for further investigation after being screened.
3.	Direct costs associated with the intervention - we assume the direct costs related to treating a given stage of bowel cancer do not vary by subgroup (though the chance of incurring these costs and the screening related costs by subgroup may vary under the different implementations of the screening programme).  This seems to be a plausible assumption in the absence of more detailed cost data at the subgroup level.  
4.	Opportunity costs from displaced activities - Opportunity costs are in the base case analysis assumed to be shared equally among all population subgroups, this assumption is explored in sensitivity analyses discussed later in this tutorial.
5.	Other cause mortality – we use the mortality rates by subgroup in the same way as discussed when deriving the baseline health distribution.  In calculating these rates we remove bowel cancer specific mortality assuming this is constant across subgroups and apply this separately in the model.
Quality adjustment of health gains to reflect morbidity – we apply the subgroup specific adjustments to quality adjust health gains resulting from the screening programme in a similar manner to that which they were applied to estimate the baseline health distribution. The population QALE distribution under no screening corresponds to our baseline health distribution as calculated in the previous section.  In our analysis of the BCSP we include an additional variable – area level proportion of population from the Indian Subcontinent (IS) – which we were unable to incorporate into our estimation of the baseline health distribution.  We assume that this IS variable is distributed independently of IMD and sex, and that it has no independent effect on baseline QALE i.e. subgroups are adjusted for other cause mortality and quality adjusted only according to their IMD and sex and these adjustments are not effected by their IS.  We next adjust the BCSP uptake parameters by subgroup.  Table I shows logistic regression results looking at gFOBT uptake in the three rounds of the BCSP pilot (3).  We use this data in combination with the proportion of invitees in each category by variable, also reported in the pilot evaluation, to get weighted average odds ratios (OR) for uptake that can be applied in the model.
TABLE I approximately here
These odds ratios are applied to a baseline rate of uptake reported  in the third round pilot where males in the youngest age group, living in the most deprived areas with the highest proportion of people from the Indian subcontinent had an uptake probability of 34%.  For example, to calculate the uptake probability for a woman of any age across all rounds of the pilot, living in the least deprived areas and with the least numbers of people from the Indian Subcontinent, we can use the following calculation.
OR = 0.34/(1-0.34) * (1.38 /0.82) * 1.13 * 0.86 * (1/0.37) * (1/0.86) = 2.71
P = OR/(1+OR) = 0.73
A similar regression analysis was reported analysing the effect of these same variables on the uptake of follow up colonoscopy.  Data were also published in the pilot study evaluation regarding the numbers of people in each category for each variable in the study.  However, cross-tabulations or correlations between the variables were not available and we therefore assumed that each variable was independently distributed to calculate the proportion of the population in each subgroup.  Table II shows our calculated gFOBT uptake, follow up colonoscopy uptake, and the proportion of the population by each subgroup.
TABLE II approximately here
Using these parameters in the model provides the total costs and health gains due to the BCSP under the standard screening approach.  
We next turn to modelling the remaining two implementations of the screening programme.  Both implementations augment the standard screening programme with additional reminders.  We derive indicative estimates of costs and impacts on screening uptake of these reminder strategies from similar interventions studied in the screening literature (7)(8), applying plausible exchange rates and inflation rates to the figures to get costs and assuming all subgroups receiving the interventions have equal additive increases in uptake.  The values used in the model for costs and impacts on gFOBT uptake for each of the strategies are given in Table III.  
TABLE III approximately here
In order to estimate total costs and health effects the model is evaluated for a representative cohort of the population – in our case a cohort of 1 million 30 year olds, as was used in the original analysis of the BCSP in the model we inherited.  The size of each subgroup is given by the population proportions calculated in Table II.  We sum the costs across all subgroups, and convert these to health opportunity costs using a threshold value of £20,000 per QALY.  These health opportunity costs are then apportioned equally to each individual in the population allowing the model to characterise net health gains in each subgroup.  For example, the total costs for the standard screening programme over the lifetime of the cohort of 1 million patients came to £72 million.  Converting this to health opportunity costs at the rate of £20,000 per QALY gives us 3,600 QALYs of health opportunity costs.  Women who live in areas with a low percentage of the population from the Indian Subcontinent (IS Q1-4), and which also fall within deprivation quintile IMD Q3, make up 10% of the population.  So we allocate 10% of this total health opportunity cost to them i.e. 360 QALYs.  This is then subtracted from the total health gains due to the BCSP in this subgroup to give the net health effect of the BCSP on this subgroup.  
The assumption of equally distributed opportunity cost is convenient, but not evidence based.  So we explore alternative assumptions in sensitivity analysis, focusing on two extreme cases where all opportunity costs are allocated to the least healthy and the healthiest subgroups, respectively.
The additional parameters that we have added to the model are assigned standard distributions by variable type, and their mean and standard error values are used to generate suitable random draws for these variables in the probabilistic sensitivity analysis (PSA).  Details of how these additional variables are dealt with in the PSA are given in Table V.  All the results presented are produced by running the model probabilistically and averaging over 1000 iterations of the model. 
The resulting health distributions estimated for each screening implementation are described below.  Figure 2a shows the gFOBT uptake by health quintile for each strategy and Figure 2b shows the colonoscopy uptake by health quintile.  QALE for each subgroup calculated from our adjusted model is given in Table IV and these are presented for our cohort by health quintile in Figure 3a and Figure 3b allowing us to better appreciate the relative impacts of the strategies.  
FIGURE 2 approximately here
TABLE IV approximately here
FIGURE 3 approximately here
TABLE V approximately here
2.1.3 Adjusting for social value judgements about fair and unfair sources of inequality
The distributions of health estimated thus far represent all variation in health in the population.  However, some variation in health may be deemed “fair” or, at least “not unfair”, perhaps because it is due to individual choice or unavoidable bad luck.  In such cases the health distributions should first be adjusted to only include health variation deemed “unfair” before measuring the level of inequality.  Social value judgements need to be made about whether or not health variation associated with each of the population characteristics is deemed fair.  In our example we have three variables to consider: sex, IMD and ethnicity.  We might make the value judgement that differences in health due to sex are fair, while differences in health due to IMD and ethnicity are unfair – this is one of eight possible value judgements that we can make on fairness in this example.  One way of adjusting our modelled health distributions for this value judgement is by using direct standardisation (9).  To do this we run a regression on our QALE distribution weighting the subgroups by the proportion of the population they represent to find the association between each variable and QALE.  An example of such a regression is given in Table VI.  We then use reference values for those variables deemed fair (i.e. sex in this case) while leaving the other variables to take the values they have in the relevant subgroups and predict out an adjusted QALE distribution.  In this example we use male as the reference value for sex and predict out the QALE distribution as shown in Table VII.  This distribution represents only the variation in health deemed unfair by the social value judgement made.  Reference values used in the adjustment process are typically population averages for continuous variables while for categorical variables the most commonly occurring category is typically used with sensitivity analysis performed on the impact of alternative choices of reference category.
TABLE VI approximately here
TABLE VII approximately here
2.2 Stage B: Evaluating Social Distributions of Health
2.2.1 Comparing interventions in terms of total health and unfair health inequality
Once we have estimated the appropriate health distributions we can then go on to characterise the distributions in terms of the twin policy goals of improving total health and reducing health inequality.  One useful piece of information for decision makers produced at this step of the analysis is the size of the health opportunity cost of choosing an intervention that reduces health inequality – this is simply the difference in total health between the intervention and a comparator.  However, this step of the analysis can also go further than that by providing information about the size of the reduction in health inequality, in terms of the difference in one or more suitable inequality indices between the intervention and a comparator.  The selection of appropriate inequality indices requires further value judgements about the nature of the inequality concern.  There are a number of commonly used indices to measure inequality that can be broadly grouped into those measuring relative inequality (scale invariant indices), those measuring absolute inequality (translation invariant) and those measuring health poverty or shortfall from a reference value.  If there is no clear choice of inequality measure it may be preferable to calculate a range of alternative measures.
Table VIII shows the results of calculating a range of relative and absolute inequality measures for the QALE distributions associated with our four screening strategies.  A higher value for each measure indicates a higher level of inequality between the most healthy and the least healthy.  
TABLE VIII approximately here
2.2.2 Ranking interventions using dominance rules
The first step in comparing distributions is looking to commonly used distributional dominance rules, as these allow strategies to be ranked with minimal restriction to the form of the underlying social welfare function. In terms of standard economic dominance rules we can note from Table IV that no-screening and standard screening are strictly dominated in the space of QALE by the universal reminder strategy – that is, no sex-IMD-ethnicity subgroup is less healthy and at least one subgroup is healthier.  However, this rule does not account for the level of inequality.  When ranking distributions based on mean health and the level of health inequality, it is possible to use alternative economic dominance rules provided by Atkinson (10) and Shorrocks (11).  These dominance rules apply when mean health is higher and inequality is lower for almost any measure of inequality.  Both rules are based around the Lorenz curve (12), a tool to analyse relative inequality constructed for health distributions by ordering the population from least healthy to most healthy and plotting the cumulative proportion of population health against the cumulative proportion of the population.  Atkinson’s theorem tests for Lorenz dominance between distributions; this means that the Lorenz curves for the distributions do not cross and the more equal distribution has at least as much mean health as the less equal distribution.  In other words, a distribution is dominated if it has higher inequality and the same or lower amount of mean health.  On these criteria the standard screening strategy is dominated by the targeted reminder.  Shorrocks’ theorem tests for generalised Lorenz dominance, wherein the Lorenz curve is multiplied by the mean health. A distribution is dominated if the generalised Lorenz curve lies wholly below that of an alternative intervention.  Under this criterion, both the targeted and universal reminder strategies dominate the no screening option.  This leaves us to compare the universal reminder and targeted reminder strategies.  While the universal reminder produces a higher average QALE overall and benefits the less deprived quintile groups more, the targeted reminder is the more equal strategy on every measure listed in Table VIII and benefits the most deprived quintile groups more.  In our example, the generalised Lorenz curves for these two distributions cross and hence we cannot use Shorrocks’ theorem to rank the distributions. 
2.2.3 Analysing trade-offs between total health and health inequality using social welfare indices
Having used distributional dominance to eliminate no screening and standard screening, in order to rank the remaining two strategies it is necessary more fully to specify an underlying social welfare function.  A number of alternative social welfare indices have been proposed that could be used to characterise the dual objectives of increasing total health and reducing health inequality.  A common feature of such functions is the need to specify the nature of and level (or value) of inequality aversion.  The inequality aversion parameters in these functions describe the trade-off between total health and the level of health inequality, i.e. the amount of total health that a decision maker would be willing to sacrifice in order to achieve a more equal distribution.  These inequality aversion parameters are difficult to interpret on the raw scale.  A more intuitive scale can be provided by combining a specific value of the parameter with a specific health distribution to derive the “equally distributed equivalent” (EDE) level of health.  The difference between the mean level of health in that distribution and the EDE level of health then represents the average amount of health per person that one would be willing to sacrifice to achieve full equality in health, given that specific value of inequality aversion.  
In this example we will use two social welfare indices closely linked to the dominance rules applied above: the Atkinson index (10) to evaluate the distributions in terms of relative inequality and the Kolm index (13) to evaluate the distributions in terms of absolute inequality.  The EDE for these social welfare indices can be calculated as follows using the inequality aversion parameters ɛ and α respectively:
Atkinson Social Welfare Index:	Kolm Social Welfare Index:
	
Figure 4a and Figure 4b show the difference in EDE health between the two strategies across different levels of inequality aversion for the relative and absolute social welfare indices respectively.  With zero inequality aversion the EDE represents the mean health, and we see that the universal strategy offers 1,000 more population QALYs compared to the targeted strategy.  For inequality aversion levels greater than ɛ =8 and α =0.12 the targeted strategy would be preferred, implying that the decision maker would be willing to sacrifice those 1,000 population QALYs in order to achieve the lower level of inequality.
FIGURE 4 approximately here
Recent work on eliciting these inequality aversion parameters from members of the general public in England (14) estimates an Atkinson ɛ parameter of about 10.95 (95% CI: 9.23-13.54) and a Kolm α parameter of about 0.15 (95% CI: 0.13-0.19).
2.3 Sensitivity analysis
There are a number of sensitivity analyses we can run to explore the impact of making alternative assumptions in our modelling on our choice of preferred strategy.  Tables IX and X present the results, respectively, of exploring (1) the impacts of alternative assumptions around the distribution of opportunity costs, and (2) the impacts of alternative social value judgements about which inequalities are considered unfair.
TABLE IX approximately here
TABLE X approximately here
 We could also perform additional sensitivity analyses including exploring alternative ways that the reminder strategies might affect the different population subgroups e.g. having constant proportional effects rather than constant absolute effects and testing for alternative underlying distributions of CRC mortality, incidence and severity. 
3. DISCUSSION
DCEA is a framework for incorporating health inequality concerns into the cost-effectiveness analysis of health care interventions.  It aims to help cost-effectiveness analysts provide decision makers with useful quantitative information about the health inequality impacts of health care interventions, and the nature and size of trade-offs between the dual objectives of improving total health and reducing health inequality.  It also aims to help cost-effectiveness analysts accommodate different value judgements about health inequality made by different decision makers and stakeholders.
Social value judgements about health inequality are complex, context-dependent and contestable.  For this reason, DCEA does not prescribe in advance any particular set of social value judgements about health inequality.  A number of social value judgements need to be made when implementing the DCEA framework, in particular regarding which dimensions of inequality are deemed unfair and the nature and strength of inequality aversion.  The framework makes these social value judgements explicit and transparent, and lends itself well to checking the sensitivity of conclusions based upon alternative plausible social value judgements.  DCEA thus aims to provide decision makers with useful quantitative information about health inequality impacts that can help to inform a deliberative decision making process, by showing how different social value judgements might or might not lead to different conclusions. Empirical work to estimate the nature and level of societal inequality aversion implicit in current healthcare allocation decisions would be useful in validating and complementing estimates of the inequality aversion levels emerging from value elicitation exercises conducted on members of the general public in England  (14).  This work would be analogous to the recent work that has been done to generate empirical estimates of the cost-effectiveness threshold (15). 
DCEA is intended to be general and flexible analytical framework that allows a diverse range of specific methods and techniques to be applied at different stages of the analysis.  In particular, the evaluation stage can in principle employ any kind of equity weighting and/or multi-criteria decision analysis to analyse trade-offs between improving total health and reducing health inequality, and is not restricted to application of the specific Atkinson and Kolm social welfare functions described in this tutorial.
We have seen in this tutorial that DCEA is demanding in terms of data, but feasible to implement in a real world context through creative application of the standard tools of economic analysis.  The data and methods we have used are inevitably partial and crude in many respects, and it is our hope that the underpinning data and technical methods will be improved and refined over the years.  Whilst the framework and methods involved may seem complex, in our opinion this complexity is well within the capabilities of analysts currently conducting standard CEA. The key to expanding the use of DCEA will be the development of better methods for assisting decision-makers to clarify and quantify the nature of their inequality concerns, and better ways of communicating findings to non-specialist audiences. 



APPENDIX
Estimating the baseline health distribution
Data on LE by IMD quintile and sex is published directly by the Office of National Statistics (16).  However, for the purposes of our analysis we also require the underlying mortality rates used to estimate these figures in order to incorporate them in the decision analytical model where all-cause mortality is separated from colorectal cancer specific mortality.   Unfortunately, these underlying mortality rates are not available by IMD quintile groups.  So to ensure we remain consistent between our baseline QALE distribution and QALE distributions associated with the various implementations of the BCSP produced by our model, we use ONS mortality rates by social class (17) to proxy those by IMD, and apply the mapping between social classes and IMD quintile groups given in Table A.I.  
TABLE A.I approximately here
We then use these mapped mortality rates to calculate the LE at birth by IMD quintile groups (2002-05) using the standard ONS methodology (18).  Table A.II compares life expectancies estimated indirectly using the mapping process described above with published direct estimates of life expectancy by IMD quintile for the same period (2002-05).  We see from the comparison that while the mapped values are on the whole reasonably close to the published values, they begin to diverge for the more deprived areas.
TABLE A.II approximately here
We next adjust these life expectancies for morbidity.  To do this we adjust for age and sex by applying the relevant weights from the published EQ-5D Norms (19) for each age range (reproduced in Table A.III) and aggregate to give and age and sex adjusted QALE. Taking the example of a male in the least deprived IMD quintile group (Q1) we can read from Table A.II that their estimated life expectancy is 80.4 years.   Using the weights in Table A.III we estimate the QALE for individuals in this subgroup as:
24*0.94 + (35-25)*0.93 + (45-35)*0.91 + (55-45)*0.84 + (65-55)*0.78 + (75-65)* 0.78 + (80.5-75)*0.75 = 69.8  QALYs
TABLE A.III approximately here
In addition to quality adjusting LE for age and sex, we also would like to adjust for variation in quality of life by area level deprivation.  In order to do this we turn to the ONS data for LE and disability free life expectancy (DFLE) by IMD quintile (16).  We assume that the average quality adjustment we have applied by using the age and sex weights captures the adjustment for the middle IMD quintile group (Q3)for each sex, and calculate relative adjustment factors for the other IMD quintile groups by further assuming the ratio of DFLE to LE is the same as the ratio of QALE to LE.  We use this data to calculate the adjustment factors shown in Table A.IV.
TABLE A.IV approximately here
Applying the adjustment factor to our QALE estimate for our male from IMD Q1 gives a refined QALE estimate taking into account area level deprivation of: 
69.8 * 1.03 = 72 QALYs 
Similar calculations for the other subgroups yield the QALE estimates in Table A.V.
TABLE A.V approximately here
Ordering the subgroups by QALE from least healthy to most healthy and adjusting for the size of each subgroup we are able to create a population distribution of QALE at birth taking into account differential mortality and morbidity by age, sex and area level deprivation.  


TABLES
Table I. Regression results of gFOBT uptake from evaluation of BCSP pilot
		Adjusted OR(95% CI)
		
Age (years)	57-59	1
	60-64	1.13(1.11 – 1.16)
	65-69	1.25(1.22 – 1.28)

Sex	Male	1
	Female	1.38(1.35 – 1.40)

Pilot Round	1	1
	2	0.77(0.76 – 0.80)
	3	0.82(0.81 – 0.84)

Deprivation Category (IMD)	Q1 (Least Deprived)	1
	Q2	0.84(0.81 -0.87)
	Q3	0.70(0.68 – 0.72)
	Q4	0.55(0.54 – 0.57)
	Q5 (Most Deprived)	0.37(0.35 – 0.38)

% Indian Subcontinent	Q1-4	1
	Q5 (Highest %)	0.86(0.84 – 0.89)



Table II. gFOBT uptake, follow up colonoscopy uptake and proportion of population by subgroup
Sex	% Indian Sub-Continent (IS)	Deprivation (IMD Quintile)	gFOBT Uptake (%)	Colonoscopy Uptake (%)	Population Proportion (%)
Male	Q1-4	Q1 (Least Deprived)	66	86	6
		Q2	62	84	9
		Q3	58	80	10
		Q4	52	79	8
		Q5 (Most Deprived)	42	77	6
	Q5 (Highest)	Q1 (Least Deprived)	63	87	1
		Q2	59	85	2
		Q3	54	81	3
		Q4	48	79	2
		Q5 (Most Deprived)	38	75	2
Female	Q1-4	Q1 (Least Deprived)	73	85	6
		Q2	70	83	9
		Q3	66	79	10
		Q4	60	77	8
		Q5 (Most Deprived)	50	76	6
	Q5 (Highest)	Q1 (Least Deprived)	70	86	1
		Q2	66	83	2
		Q3	62	79	3
		Q4	56	78	2
		Q5 (Most Deprived)	46	76	2




Table III. Costs and impact on gFOBT uptake of reminder strategies
Strategy	Cost per recipient	Increase in gFOBT uptake per recipient
Universal reminder	£3.50	6%
Targeted reminder	£7.00	12%





Table IV. QALE distribution by subgroup under each strategy
			QALE
Sex	% Indian Sub-Continent (IS)	Deprivation (IMD Quintile)	Baseline	Standard	Targeted	Universal
Male	Q1-4	Q1 (Least Deprived)	72.16	72.21	72.20	72.21
		Q2	70.48	70.52	70.52	70.52
		Q3	69.09	69.12	69.12	69.13
		Q4	66.61	66.63	66.63	66.63
		Q5 (Most Deprived)	60.22	60.24	60.24	60.24
	Q5 (Highest)	Q1 (Least Deprived)	72.16	72.20	72.21	72.21
		Q2	70.48	70.52	70.52	70.52
		Q3	69.09	69.12	69.13	69.12
		Q4	66.61	66.63	66.63	66.63
		Q5 (Most Deprived)	60.22	60.23	60.24	60.23
Female	Q1-4	Q1 (Least Deprived)	74.84	74.91	74.91	74.92
		Q2	73.10	73.16	73.16	73.17
		Q3	71.77	71.82	71.81	71.82
		Q4	69.19	69.23	69.24	69.23
		Q5 (Most Deprived)	63.17	63.20	63.20	63.20
	Q5 (Highest)	Q1 (Least Deprived)	74.84	74.91	74.92	74.91
		Q2	73.10	73.16	73.17	73.16
		Q3	71.77	71.81	71.82	71.82
		Q4	69.19	69.23	69.24	69.23
		Q5 (Most Deprived)	63.17	63.20	63.20	63.20
Overall Average			69.260	69.300	69.301	69.302



Table V. Distributions and parameter values used in PSA for additional parameters added to model
Parameter	Explanation
gFOBT and colonoscopy uptake	Uncertainty on these calculated in PSA assuming ln(OR) distributed normally. The variance covariance matrices for the uptake regressions were not available to us so we drew each coefficient independently and combined to create uptake probabilities.
Mortality rates	Adjusted for uncertainty by the underlying model.
Quality adjustment 	Used beta distribution with the mean and standard error values as reported in the UK EQ-5D norms.
Cost of reminders	As no data was given on the uncertainty we assume a 10% standard error and used this to draw values from the appropriate gamma distributions.
Impact of reminders on uptake	Reported mean and standard errors values used to draw from the appropriate beta distributions.




TableVI. Fairness adjustment regression
	Coefficient(SE)
Constant	74.92(4.37E-05)
IS Q1-4 	-0.004(2.56E-05)
Male	-2.708(5.47E-05)
IMD Q2	-1.75(4.91E-05)
IMD Q3	-3.097(4.84E-05)
IMD Q4	-5.675(5.02E-05)
IMD Q5	-11.71(5.33E-05)
Male*IMD Q2	0.065(6.95E-05)
Male*IMD Q3	0.015(6.84E-05)
Male*IMD Q4	0.104(7.10E-05)
Male*IMD Q5	-0.259(7.532E-05)






TableVII. Fairness adjusted health distribution reference sex = male
			QALE
Sex	% Indian Sub-Continent (IS)	Deprivation (IMD Quintile)	Targeted	Targeted Adjusted
Male	Q1-4	Q1 (Least Deprived)	72.20	72.20
		Q2	70.52	70.52
		Q3	69.12	69.12
		Q4	66.63	66.63
		Q5 (Most Deprived)	60.24	60.24
	Q5 (Highest)	Q1 (Least Deprived)	72.21	72.21
		Q2	70.52	70.52
		Q3	69.13	69.13
		Q4	66.63	66.63
		Q5 (Most Deprived)	60.24	60.24
Female	Q1-4	Q1 (Least Deprived)	74.91	72.20
		Q2	73.16	70.52
		Q3	71.81	69.12
		Q4	69.24	66.63
		Q5 (Most Deprived)	63.20	60.24
	Q5 (Highest)	Q1 (Least Deprived)	74.92	72.21
		Q2	73.17	70.52
		Q3	71.82	69.13
		Q4	69.24	66.63
		Q5 (Most Deprived)	63.20	60.24





Table VIII. Inequality measures calculated for four screening strategies
Relative Inequality Indices	no screening	standard	targeted reminder	universal reminder
 Relative Gap Index (ratio) 	0.17527*	0.17592	0.17586	0.17596
 Relative Index of Inequality (RII) 	0.18607*	0.18674	0.18668	0.18678
 Gini Index 	0.03101*	0.03112	0.03111	0.03113
 Atkinson Index (ε=1) 	0.00171*	0.00172	0.00172	0.00172
 Atkinson Index (ε=7)	0.01330*	0.01337	0.01337	0.01338
 Atkinson Index (ε=30) 	0.06253*	0.06281	0.06279	0.06283

Absolute Inequality Indices	no screening	standard	targeted reminder	universal reminder
 Absolute Gap Index (range) 	10.98604*	11.03064	11.02726	11.03325
 Slope index of inequality (SII) 	12.88747*	12.94123	12.93691	12.94438
 Kolm Index (α=0.025) 	0.20281*	0.20430	0.20416	0.20439
 Kolm Index (α=0.1)	0.87801*	0.88429	0.88371	0.88467
 Kolm Index (α=0.5) 	4.56391*	4.58739	4.58587	4.58883
* indicates the most equal strategyε=1 represents low relative inequality aversion while ε=30 represents high relative inequality aversionα=0.025 represents low absolute inequality aversion while α=0.5 represents high absolute inequality aversion





Table IX. Sensitivity to alternative opportunity cost distributions
	All opportunity cost borne by least healthy subgroup		All opportunity cost borne by healthiest subgroup
Social Welfare Indices	no screening	standard	targeted reminder	universal reminder		targeted reminder	universal reminder
 Mean Health 	69.25969	69.30006	69.30127	69.30233*		69.30127	69.30233*
 Atkinson EDE (ε=1) 	69.14152	69.18056	69.18147	69.18252*		69.18286	69.18373*
 Atkinson EDE (ε=7) 	68.33888	68.36800*	68.36610	68.36734		68.37799*	68.37769
 Atkinson EDE (ε=30) 	64.92865*	64.91468	64.89302	64.89892		64.95627*	64.95350
 Kolm EDE (α=0.025) 	69.05688	69.09486	69.09556	69.09660*		69.09793	69.09866*
 Kolm EDE (α=0.1) 	68.38168	68.41112*	68.40958	68.41074		68.42046*	68.42020
 Kolm EDE (α=0.5) 	64.69578*	64.68086	64.65951	64.66532		64.72148*	64.71879
* indicates the strategy yielding the highest social welfare




Table X. Sensitivity to alternative social value judgements
Social Value Judgment	Preferred Strategy based on Social Welfare Index
IMD	Ethnic Diversity	Sex	Atkinson EDE (ε=1)	Atkinson EDE (ε=7)	Atkinson EDE (ε=30)	Kolm EDE (α=0.025)	Kolm EDE (α=0.1)	Kolm EDE (α=0.5)
Fair	Fair	Fair	U	U	U	U	U	U
Fair	Unfair	Fair	U	U	U	U	U	U
Fair	Fair	Unfair	U	U	U	U	U	U
Fair	Unfair	Unfair	U	U	U	U	U	U
Unfair	Fair	Fair	U	U	T	U	U	T
Unfair	Unfair	Fair	U	U	T	U	U	T
Unfair	Fair	Unfair	U	U	T	U	U	T
Unfair	Unfair	Unfair	U	U	T	U	U	T
U = universal reminder, T = targeted reminder




Table A.I. Mapping between IMD quintile groups and social class
Deprivation (IMD Quintile)	Social Class
Q1 (Least Deprived)	I&II (Professional occupations & Managerial and technical occupations)
Q2	I&II (Professional occupations & Managerial and technical occupations)
Q3	IIIN (Skilled non-manual occupations)
Q4	IIIM (Skilled manual occupations)
Q5 (Most Deprived)	IV&V (Partly-skilled occupations & Unskilled Occupations)




Table A.II. Comparison between mapped and published LE by IMD quintile group
Sex	Deprivation (IMD Quintile)	LE by Mapped IMD Quintiles (years)	LE Published IMD Quintiles (years)	Difference (Mapped – Published)
Male	Q1 (Least Deprived)	80.4	80.0	0.4
	Q2	80.4	78.6	1.8
	Q3	79.2	77.3	1.9
	Q4	77.7	75.4	2.3
	Q5 (Most Deprived)	76.2	72.2	4.0
Female	Q1 (Least Deprived)	83.7	83.2	0.5
	Q2	83.7	82.3	1.4
	Q3	82.6	81.5	1.1
	Q4	81.1	80.1	1.0
	Q5 (Most Deprived)	80.3	77.9	2.4




Table A.III. QALY weights by age and sex based on EQ-5D norms
Age	Male 	Female
0-25	0.94	0.94
25-34	0.93	0.93
35-44	0.91	0.91
45-54	0.84	0.85
55-64	0.78	0.81
65-74	0.78	0.78
75+	0.75	0.71






Table A.IV. Using LE and DFLE to calculate QALE adjustment factors by IMD
Sex	Deprivation (IMD Quintile)	LE	DFLE	Ratio DFLE/LE	QALE Adjustment Factor 
Male	Q1 (Least Deprived)	80.0	67.3	0.84	1.03
	Q2	78.6	64.3	0.82	1.00
	Q3	77.3	63.4	0.82	1.00
	Q4	75.4	59.7	0.79	0.96
	Q5 (Most Deprived)	72.2	54.2	0.75	0.91
Female	Q1 (Least Deprived)	83.2	67.8	0.81	1.02
	Q2	82.3	65.7	0.80	1.00
	Q3	81.5	64.9	0.80	1.00
	Q4	80.1	61.8	0.77	0.97
	Q5 (Most Deprived)	77.9	57.2	0.73	0.92




Table A.V. QALE by sex and deprivation
Sex	Deprivation (IMD Quintile)	QALE
Male	Q1 (Least Deprived)	72.2
	Q2	70.5
	Q3	69.1
	Q4	66.6
	Q5 (Most Deprived)	60.2
Female	Q1 (Least Deprived)	74.8
	Q2	73.1
	Q3	71.8
	Q4	69.2
	Q5 (Most Deprived)	63.2


FIGURES

Figure 1: Baseline health distribution
Figure 2a: gFOBT uptake distribution by strategy	Figure 2b: colonoscopy uptake distribution

Figure 3a: Health compared to no screening  (per million of population invited for screened)  	Figure 3b: Health compared to standard screening (per million of population invited for screening) 


 Figure 4a: Sensitivity to level of relative inequality aversion	 Figure 4b: Sensitivity to level of absolute inequality aversion
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